[HTML][HTML] Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma

…, D Schadendorf, H Gogas, J Zoco… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
… Savage, MSc, MD, 15 Vanna Chiarion-Sileni, MD, 16 Catalin Mihalcioiu, MD, 17 Cornelia
Mauch, MD, PhD, 18 Ana Arance, MD, PhD, 19 Francesco Cognetti, MD, 20 Lars Ny, MD …

Novel Alzheimer risk genes determine the microglia response to amyloid‐β but not to TAU pathology

…, N Fattorelli, N Thrupp, E Salta, J Zoco… - EMBO molecular …, 2020 - embopress.org
Polygenic risk scores have identified that genetic variants without genome‐wide significance
still add to the genetic risk of developing Alzheimer's disease ( AD ). Whether and how …

[HTML][HTML] Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: Results from the phase 3b/4 CheckMate 920 …

…, DJ George, T Hutson, J Zhang, J Zoco… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Original research: Safety and efficacy of nivolumab plus ipilimumab in patients with advanced
non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial - PMC …

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920

…, TE Hutson, ER Arrowsmith, J Zhang, J Zoco… - Cancer, 2022 - Wiley Online Library
Background Nivolumab plus ipilimumab (NIVO + IPI) has demonstrated long‐term efficacy
and safety in patients with previously untreated, advanced renal cell carcinoma (aRCC). …

Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.

…, IM Svane, M Ajaz, NI Khushalani, M Lobo, J Zoco… - 2021 - ascopubs.org
9516 Background: NIVO 1 mg/kg plus IPI 3 mg/kg (NIVO1 + IPI3) is approved for treatment (tx)
of unresectable/adv melanoma, with demonstrated durable clinical benefit on long-term …

Nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma (nccRCC): Safety and efficacy from CheckMate 920.

…, DJ George, TE Hutson, J Zhang, J Zoco… - 2021 - ascopubs.org
309 Background: The long-term efficacy and tolerability of nivolumab (NIVO) 3 mg/kg +
ipilimumab (IPI) 1 mg/kg Q3W × 4 doses followed by NIVO 3 mg/kg Q2W for previously untreated …

Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and low Karnofsky performance status: Results from the …

…, IJ Percent, SS Tykodi, MR Harrison, J Zhang, J Zoco… - 2021 - ascopubs.org
315 Background: Combination therapy with nivolumab + ipilimumab (NIVO+IPI) has
demonstrated long-term efficacy and tolerability for patients (pts) with previously untreated …

Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 …

…, DJ George, TE Hutson, E Arrowsmith, J Zhang, J Zoco… - 2021 - ascopubs.org
4515 Background: Combination therapy with nivolumab plus ipilimumab (NIVO+IPI) has
demonstrated long-term efficacy and tolerability in patients with previously untreated advanced …

Taller literario

…, A García, C Vacas Belda, JM Zoco Latasa - Vida …, 1983 - redined.educacion.gob.es
Soneto a mis alumnos Page 1 Soneto a mis alumnos se que está al final tan silencioso, que
esconde entre sus libros la cabeza es un reflejo fiel y misterioso de una niñez perdida entre …

Inserción laboral de la población gitana. Dificultades: visión social y empresarial

MJ Zoco Izu - 2017 - academica-e.unavarra.es
El pueblo gitano ha sufrido muchos cambios, desde una vida más nómada hasta llegar a
asentarse en los núcleos urbanos, siempre han estado marcados por una serie de …